Person:
DANE, FAYSAL

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

DANE

First Name

FAYSAL

Name

Filters

Reset filters

Settings

Author: ATASOY, BESTE MELEK × Has files: false ×

Search Results

Now showing 1 - 10 of 13
  • No Thumbnail Available
    PublicationMetadata only
    The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy
    (SPRINGER, 2012) ATASOY, BESTE MELEK; Atasoy, Beste M.; Yonal, Oya; Demirel, Birsen; Dane, Faysal; Yilmaz, Yusuf; Kalayci, Cem; Abacioglu, Ufuk; Imeryuz, Nese
    To investigate the impact of early insertion of percutaneous endoscopic gastrostomy-tube on nutritional status and completeness of concurrent chemotherapy in locally advanced head and neck cancer patients treated with chemoradiotherapy. Twenty-three patients were enrolled into this prospective study. Gastrostomy-tube was inserted in patients before the initiation of chemoradiotherapy. There was not any significant change in nutritional parameters of patients that used their tube during treatment. Despite the grade 3 mucositis, the planned concurrent chemotherapy could be given in 70% of the patients. However, nine patients had weak compliance and their body weight (P = 0.01) and body mass index (P = 0.01) deteriorated in the first 4 weeks of chemoradiotherapy. The completeness of concurrent chemo-rate was 44% in these patients. Toxicity, requiring aggressive supportive care, may limit the chemotherapy part of curative concomitant chemoradiotherapy. By providing adequate enteral nutrition the insertion of gastrostomy-tube can increase the completeness rate of concurrent chemotherapy.
  • No Thumbnail Available
    PublicationMetadata only
    Grad III anaplasti̇k gli̇al tümör tanili hastalarda radyoterapi̇yle eş zamanli adjuvan temozolami̇d sonuçlari tek merkez deneyi̇mi̇
    (2014-05-23) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; DANE, FAYSAL; Sahibov E., Atasoy B. M., Şeker A., Özgen Z., Dane F., Ziyal M. İ., Abacıoğu U.
  • No Thumbnail Available
    PublicationMetadata only
    Rektum kanseri̇ni̇n adjuvan tedavi̇si̇nde radyoterapi̇yle eş zamanli tegafur urasi̇l uft foli̇ni̇k asi̇t fa uygulamasi tolerabi̇li̇te değerlendi̇rmesi̇
    (2006-04-19) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; DANE, FAYSAL; YUMUK, PERRAN FULDEN; ATASOY B. M. , ABACIOĞLU U., ÖZGEN Z., DANE F., YUMUK P. F. , MAYADAĞLI A., TURHAL S., ŞENGÖZ K. M.
  • No Thumbnail Available
    PublicationMetadata only
    Health-Related Quality of Life During Postoperative Chemoradiotherapy with Oral Uracil-Tegafur and Leucovorin in Rectal Cancer Patients
    (H G E UPDATE MEDICAL PUBLISHING S A, 2013) ATASOY, BESTE MELEK; Ozgen, Zerrin; Ozden, Sevgi; Dane, Faysal; Atasoy, Beste M.; Akgunt, Zuleyha; Yumuk, P. Fulden; Mayadagli, Alpaslan; Turhal, N. Serdar; Abacioglu, Ufuk
    Background/Aims: The objective of this study was to report on the quality of life of locally advanced rectal cancer patients that were treated with uracil-tegafur (UFT)/leucovorin (LV)-based concurrent chemoradiotherapy. Methodology: Twenty-five patients were enrolled into this prospective study. Radiotherapy (50.4Gy) was given with concurrent UFT (300mg/m(2)/day) and LV (30mg/day). Turkish versions of EORTC-QLQC30 and EORTC QLQCR38 were applied at the beginning (HROoL-1) and at the end (HRQoL-2) of chemoradiotherapy. Paired samples t-test was used to compare the difference of means for each scale between HRQoL1 and HRQoL2 and p values <0.05 were considered statistically significant. Results: Study compliance was 80.6%. From baseline to the end of chemoradiotherapy, the mean scores of dyspnea (p=0.006) diarrhea (p=0.005) and micturition (p=0.005) increased significantly. Chemotherapy side effects also increased at the end of therapy (p=0.07). Seventy-six percent (76%) of male patients replied to questions related to sexual problems and functions, whereas no female patients replied. Conclusions: Although, diarrhea and micturition are the major problems, quality of life scores indicate that concurrent oral fluoropyrimidine-based chemoradiotherapy is a feasible treatment.
  • No Thumbnail Available
    PublicationMetadata only
    Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer
    (TURKISH SOC GASTROENTEROLOGY, 2011) ATASOY, BESTE MELEK; Atasoy, Beste Melek; Dane, Faysal; Kefeli, Aysegul Ucuncu; Caglar, Hale; Cingi, Asim; Turhal, Nazim Serdar; Abacioglu, Ufuk; Yegen, Cumhur
    Background/aims: This study aimed to demonstrate the efficacy and tolerability of low-dose weekly gemcitabine as a radiosensitizer in unresectable pancreatic cancer patients treated with chemoradiotherapy. Methods: Twenty-four histologically confirmed pancreatic carcinoma patients (female/male: 10/14, median age: 60) were evaluated. Seven (29%) patients received gemcitabine either as a single agent or in combination prior to chemoradiotherapy. Concurrent 75 mg/m(2) gemcitabine was infused weekly. Radiotherapy was delivered to the primary tumor and positive lymphatics with 3D-conformal radiotherapy to a total dose of 4500 cGy. Local progression-free survival, distant metastasis-free survival and overall survival were evaluated by Kaplan-Meier method. Results: Median follow-up was 36 weeks. Median local progression-free survival, distant metastasis-free survival and overall survival were 22 weeks (95% confidence interval [CI]: 5-59 weeks), 19 weeks (95%CI: 6.9-31 weeks) and 36 weeks (95%CI: 28-43 weeks), respectively. All patients completed radiotherapy as scheduled. Concurrent gemcitabine was given fully in 58.3% of patients. Gemcitabine was terminated in four (16.6%) patients due to grade 3 neutropenia (n=1), grade 3 nausea/vomiting (n=2) or patient's reluctance (n=1). Patients with local response and stable disease to chemoradiotherapy revealed a median survival of 39 weeks (95%CI: 30-47.9 weeks) compared to 36 weeks (95%CI: 9.7-62.2 weeks) in patients with locally progressive disease (p=0.52). Pain was improved in 50% of patients. Conclusions: Weekly low-dose radiosensitizing gemcitabine is effective and safe in unresectable pancreatic cancer patients.
  • No Thumbnail Available
    PublicationMetadata only
    Kanser tanisi alan hastalarda poli̇kli̇ni̇k şartlarinda üç farkli test İle nütri̇syonel durum değerlendi̇rmesi̇
    (2012-04-19) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; DANE, FAYSAL; YUMUK, PERRAN FULDEN; Atasoy B. M., Aygör H. A., Günaydın D., Özlen T., İbrahimov R., Özgen Z., Dane F., Yumuk P. F.
  • No Thumbnail Available
    PublicationMetadata only
    Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience
    (SAGE PUBLICATIONS LTD, 2021) ATASOY, BESTE MELEK; Alan, Ozkan; Telli, Tugba Akin; Tuylu, Tugba Basoglu; Arikan, Rukiye; Demircan, Nazim Can; Ercelep, Ozlem; Kaya, Serap; Babacan, Nalan Akgul; Atasoy, Beste M.; Bozkurt, Suheyla; Bayri, Yasar; Gul, Dilek; Ekinci, Gazanfer; Ziyal, Ibrahim; Dane, Faysal; Yumuk, P. Fulden
    Purpose Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor, and the prognosis is generally extremely poor. In this retrospective study, we analyzed the outcome of systemic treatment in recurrent high-grade glioma patients and the impact of prognostic factors on survivals. Methods Data from 114 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 were retrospectively analyzed. Eastern Cooperative Oncology Group (ECOG) performance status, age, gender, histology, type of surgical resection, side effects after systemic treatment (deep vein thrombosis, hypertension, proteinuria), IDH1 and alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutation status were investigated as prognostic factors for progression-free survival and overall survival. Results At the time of diagnosis, the median age was 48 (17-77) and 68% of the patients were male. Most common pathologic subtype was glioblastoma multiforme (68%). Median follow-up duration was 9.1 months (1-68 months). Median progression-free survival and overall survival were 6.2 months and 8 months, respectively. In multivariate analysis, ECOG PS, deep venous thrombosis and the presence of ATRX and IDH1 mutation were found to be independent prognostic factors for progression-free survival (p < 0.05) and, ECOG PS, the presence of ATRX and IDH1 mutation for overall survival (p < 0.05). Conclusion Our study is real life data and the median progression-free survival and overall survival rates are similar to the literature. We have found ECOG PS, presence of ATRX and IDH1 mutation to be independent prognostic factors for both progression-free survival and overall survival.
  • No Thumbnail Available
    PublicationMetadata only
    Prophylactic feeding with immune-enhanced diet ameliorates chemoradiation-induced gastrointestinal injury in rats
    (TAYLOR & FRANCIS LTD, 2010) ATASOY, BESTE MELEK; Atasoy, Beste M.; Deniz, Mustafa; Dane, Faysal; Ozen, Zeynep; Turan, Pinar; Ercan, Feriha; Cerikcioglu, Nilguen; Aral, Cenk; Akgun, Zueleyha; Abacioglu, Ufuk; Yegen, Berrak C.
    Materials and methods: Forty-eight Sprague-Dawley rats were divided into control (C, n = 6), irradiation (IR, n = 14), fluoropyrimidine (5-FU, n = 14)-treated, IR + 5-FU (n = 14)-treated groups. Half of each irradiated and/or 5-FU-treated groups were previously fed with IED containing arginine, omega-3-fatty acids and RNA fragments, while the other half were fed a standard rat diet (SD) for eight days before the induction of IR or injection of 5-FU. In IR groups, whole abdominal irradiation (11 Gy) was performed with 6 MV photons. In the 5-FU groups, fluoropyrimidine (100 mg/kg) was administered intraperitoneally 30 min prior to irradiation. All animals were sacrificed on the 4th day of IR or 5-FU injection. Results: Bacterial colony counts in the ceca and mesenteric lymph nodes of IED-fed rats, which have received either 5-FU and/or irradiation were significantly lower than the corresponding SD-fed groups. Morphometric results revealed that gastric, ileal and colonic injuries were less in IED-treated IR or IR + 5-FU + IED groups, as compared to SD-fed groups. However, IED did not alter DNA fragmentation ratios. Conclusion: Prophylactic feeding of IED has a protective effect on chemoradiation-induced gastrointestinal injury, which appears to involve the eradication of bacterial overgrowth.
  • No Thumbnail Available
    PublicationMetadata only
    Rektum kanseri̇ni̇n adjuvan tedavi̇si̇nde oral floropi̇ri̇mi̇di̇n foli̇ni̇k asi̇tle eş zamanli radyoterapi̇ uygulamasinin yaşam kali̇tesi̇ne etki̇si̇
    (2012-04-19) ÖZGEN, ZERRİN; DANE, FAYSAL; ATASOY, BESTE MELEK; YUMUK, PERRAN FULDEN; Özgen Z., Dane F., Özden S., Akgün Z., Atasoy B. M., Yumuk P. F., Mayadağlı A., Turhal S., Abacıoğlu U.
    Amaç: Bu çalışmada rektum kanserinin adjuvan tedavisinde oral fl oropirimidin-folinik asitle eş zamanlı radyoterapi uygulamasının yaşam kalitesine etkisinin araştırılması amaçlandı. Gereç-Yöntem: Prospektif planlanan bu faz II çalışmada Ekim 2003-Aralık 2005 tarihleri arasında WHO performans skoru 0-1, evresi pT3-T4pN+, histopatolojisi adenokanser olan ve yazılı onamı alınmış yaşam kalitesi formlarını dolduran 25 hasta analize dahil edildi. Protokole göre pelvik radyoterapi (RT) konvansiyonel fraksiyon şemasıyla kemoterapi (KT) oral fl oroprimidin-UFT 300 mg/m2/ gün, folik asit 30 mg/m2/gün eş zamanlı olarak toplam 50.4 Gy/28 fraksiyon/5 haftada uygulandı. Çalışmada Avrupa Kanser Araştırma ve Tedavisi Organizasyonu (EORTC) yaşam kalitesi grubunun izni alınarak EORTC-QLQC30 genel sağlık ve EORTC QLQCR38 kolorektal kanser yaşam kalitesi formlarının Türkçe sürümleri kullanıldı. Formlar kemoradyoterapinin (KRT) başında (KRT1) ve tedavi bitiminde (KRT2) birer kez uygulandı. Yaşam kalitesi skorları 0-100 arasında hesaplandı ve ortalama değerleriyle (±standart sapma) verildi. Yüksek skor, fonksiyonel skalada sağlık durumunun iyiliğini semptom skalasında semptomun fazlalığını göstermekteydi. Zamana bağlı değişkenlerin ortalamalarının karşılaştırılmasında ilişkili örneklemler için t testi (paired-sample t test) kullanıldı. Anlamlılık için p değeri <0.05 seçildi. KRT sırasında görülen yan etkilerin değerlendirilmesi genel toksisite kriterleri (CTC) v2.0’a göre yapıldı. Bulgular: Tüm hastalar RT’yi planlandığı şekilde tamamlandı. Eş zamanlı KT uygulaması %84 hastada kesintisiz gerçekleşti. Yan etkilerden derece 2 diyare %25, derece 2 dizüri %10, derece 3 dizüri %10 oranında izlendi. Hastaların tamamı KRT başında yaşam kalitesi formalarını doldurmuşken KRT sonu tamamlama oranı %96 idi. Formlarda yer alan sorulardan genel sağlık durumunu, fiziksel fonksiyonları ve semptomları sorgulayan sorulara hastaların tamamı cevap verdi. Buna karşılık seksüel fonksiyon sorularına erkek hastalar %76 oranında cevap verirken kadınların hiçbirisi sorulara cevap vermedi. KRT başı ve sonu ortalama skorlardan anlamlı fark görülenler şu şekildeydi: diyare (KRT1:18.66±32.03; KRT2:43.99±35.64, p=0.01), idrar problemleri (KRT1: 34.66±24.49; KRT2:51.55±30.41, p=0.006), kemoterapiye bağlı yan etkiler (KRT1: 21.33±15.35; KRT2: 29.33±24.40, p=0.05). Bu parametreler dışında yer alan global sağlık durumu skoru, fonksiyonel durum parametreleri ve semptom skorları arasında KRT1-KRT2 karşılaştırmasında anlamlı fark bulunmadı. Semptom skalasında emosyonel ve insomnia skorları KRT başında kadınlarda kötü iken, fiziksel skorlar erkeklerde daha kötüydü. KRT sonu bu farkların kaybolduğu izlendi. Sonuç: Çalışmamızda rektum kanseril tanısı alan hastalarda oral fl oropirimidin ile eş zamanlı KRT uygulamasının diyare ve idrar probleri dışında yaşam kalitesine olumsuz etkisinin olmadığı görülmüştür. Çalışmamız yüksek hasta sayılı ve uzun takipli çalışmalarla desteklenmelidir.
  • No Thumbnail Available
    PublicationMetadata only
    Long-term neuromusculoskeletal side effects and quality of life in nasopharyngeal cancer patients receiving radiochemotherapy
    (SPRINGER, 2020) ATASOY, BESTE MELEK; Kefeli, Aysegul Ucuncu; Sanal-Toprak, Canan; Asedov, Ruslan; Ozen, Zeynep; Akyuz, Gulseren; Dane, Faysal; Atasoy, Beste M.
    Aim In this study, we aimed to evaluate the neuromusculoskeletal late side effects and their impact on the quality of life of patients with nasopharyngeal carcinoma treated with radiochemotherapy. Patients and methods Twenty-seven patients were included. The mean follow-up was 61 months (range, 18-111 months). The median external radiotherapy dose applied to the nasopharynx and primary tumor was 70 Gy (range, 61-73 Gy). The mean dose received by the temporomandibular joint in the dose-volume histograms of these patients was 60.7 Gy. The maximal doses of the muscles responsible for cervical motion in different ranges were greater than 60 Gy, and the mean doses were greater than 40 Gy in the muscle groups, except for the extensor muscles. Results Two patients had brachial plexus involvement, while 89% of the patients had restriction in flexion and extension movements. Of the patients, 52% had trismus. There was a significant correlation between extension restriction and general heath score and the physical subscale of the quality-of-life questionnaire (p = 0.01). There was also a correlation between trismus and pain killer usage (p = 0.004). Conclusion This is the first study to analyze long-term muscle and nerve toxicity and their correlation between doses in nasopharyngeal cancer patients following radiochemotherapy. Despite the advances in radiotherapy techniques, it is necessary to pay attention to the doses of the nerves and muscles for late effects.